TY - JOUR
T1 - Neutrophilic myelofibrosis presenting as philadelphia chromosome negative BCR non‐rearranged chronic myeloid leukemia
AU - Stewart, Keith
AU - Carstairs, Kelvin C.
AU - Dubé, Ian D.
AU - Keating, Armand
PY - 1990/5
Y1 - 1990/5
N2 - Chronic myeloid leukemia consists of Philadelphia chromosome positive disease in 90% of cases, and a further 5%, although Philadelphia chromosome negative, exhibit bcr gene rearrangements consistent with the disease. The remaining 5% of cases have a heterogeneous clinical picture with a course unlike that of classical chronic myeloid leukemia, and may belong to different pathologic entities. We report five cases belonging to the latter group, initially identified as Philadelphia chromosome negative, bcr non‐rearranged chronic myeloid leukemia, that developed progressive leucocytosis, absolute monocytosis, myelodysplasia, extramedullary hematopoiesis, and had evidence of myelofibrosis. These cases may represent a distinct clinical entity characterized by neutrophilic myelofibrosis, which can be identified prospectively by clinical and pathologic criteria. Standard therapy for treating chronic myeloid leukemia or idiopathic myelofibrosis may not be appropriate for this group.
AB - Chronic myeloid leukemia consists of Philadelphia chromosome positive disease in 90% of cases, and a further 5%, although Philadelphia chromosome negative, exhibit bcr gene rearrangements consistent with the disease. The remaining 5% of cases have a heterogeneous clinical picture with a course unlike that of classical chronic myeloid leukemia, and may belong to different pathologic entities. We report five cases belonging to the latter group, initially identified as Philadelphia chromosome negative, bcr non‐rearranged chronic myeloid leukemia, that developed progressive leucocytosis, absolute monocytosis, myelodysplasia, extramedullary hematopoiesis, and had evidence of myelofibrosis. These cases may represent a distinct clinical entity characterized by neutrophilic myelofibrosis, which can be identified prospectively by clinical and pathologic criteria. Standard therapy for treating chronic myeloid leukemia or idiopathic myelofibrosis may not be appropriate for this group.
KW - Philadelphia negative CML
KW - germline BCR
KW - myelodysplasia
UR - http://www.scopus.com/inward/record.url?scp=0025344019&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025344019&partnerID=8YFLogxK
U2 - 10.1002/ajh.2830340113
DO - 10.1002/ajh.2830340113
M3 - Article
C2 - 2327406
AN - SCOPUS:0025344019
SN - 0361-8609
VL - 34
SP - 59
EP - 63
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 1
ER -